POLQ inhibitors
AssigneeAstraZeneca AB
InventorsBernard Barlaam, Michael Bodnarchuk, Gail Wrigley, Jon Winter-Holt, Oliver Turner, Ariamala Gopalsamy, Jason Shields, Sofia Ferrer Cabrera, Helen Elizabeth Jones
Life of this patent
Estimating the term…
Abstract
The specification generally relates to compounds of Formula (I): or a stereoisomer or pharmaceutically salt thereof, wherein G, Ga, Gb, X, Y, R1, R2, Q1, Q2, and Q3 have any of the meanings defined herein, together with compositions containing them and their use in therapy. The compounds are inhibitors of the polymerase, DNA polymerase theta (Polθ or POLQ), and are thereby particularly useful in the treatment of cancer.
Claims24
A compound which is 2-(3-chloro-4-(6-(1-methylcyclopropoxy)-9-((4-methylpyridin-2-yl)methyl)-9H-purin-8-yl)phenoxy)-N,N-dimethylethan-1-amine:
- or a pharmaceutically acceptable salt thereof.
A compound selected from (R)-4-(3-chloro-4-(9-(3-chlorobenzyl)-6-(1-methylcyclopropoxy)-9H-purin-8-yl)phenoxy)-2-methylbutanoic acid and (S)-4-(3-chloro-4-(9-(3-chlorobenzyl)-6-(1-methylcyclopropoxy)-9H-purin-8-yl)phenoxy)-2-methylbutanoic acid:
- or a pharmaceutically acceptable salt thereof.
A compound selected from (R)-1-(3-chloro-4-(6-(1-methylcyclopropoxy)-9-((4-methylpyridin-2-yl)methyl)-9H-purin-8-yl)phenoxy)propan-2-ol and (S)-1-(3-chloro-4-(6-(1-methylcyclopropoxy)-9-((4-methylpyridin-2-yl)methyl)-9H-purin-8-yl)phenoxy)propan-2-ol:
- or a pharmaceutically acceptable salt.
Dependencies are inferred from the claim text.